SCHEMBL18758161

SCHEMBL18758161

O=C(ON1C(=O)CCC1=O)C(CCSS)S(=O)(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17696618 0.86 SMN1; SMN2 (0.31)
SCHEMBL22104691 0.84
SCHEMBL19220325 0.84
SCHEMBL17694234 0.83 MGLL (0.30)
SCHEMBL16153543 0.81 RECQL (0.34)
SCHEMBL8757607 0.80
SCHEMBL18726698 0.78 PARL (0.35)
SCHEMBL28437179 0.78 RECQL (0.33)
SCHEMBL28469683 0.78 KMT2A (0.38)
SCHEMBL17344122 0.78 RECQL (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202947-A1 METHODS OF PREVENTING METHIONINE OXIDATION IN IMMUNOCONJUGATES IMMUNOGEN, INC. 2022-06-30 US disclosed
US-20190111147-A1 METHODS OF PREVENTING METHIONINE OXIDATION IN IMMUNOCONJUGATES IMMUNOGEN, INC. 2019-04-18 US disclosed
US-20190031712-A1 Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates IMMUNOGEN, INC. 2019-01-31 US disclosed
US-10035817-B2 Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane IMMUNOGEN, INC. (US) 2018-07-31 US disclosed
US-20170106095-A1 ANTIBODY DRUG CONJUGATES NOVARTIS AG (CH) 2017-04-20 US disclosed